Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Sonoma Pharmaceuticals (Nasdaq:SNOA) reported fourth-quarter FY2026 results for the quarter ended March 31, 2026. Revenue rose to $5.6M (+48%) from $3.8M; gross profit was $2.2M (39%). Net loss was $0.6M, and EBITDA loss improved 66% to $0.2M. For FY2026, revenue increased to $19.5M (+$5.2M) and EBITDA loss fell 38% to $2.1M. Cash was $2.4M.
How this was made
The 30-second read
Why it matters
This is a full FY and Q4 results release with quantified revenue growth and narrowing EBITDA losses, plus regional commentary on where growth did and did not occur.
Market read
Traders can update SNOA’s near-term fundamentals based on the disclosed revenue acceleration and improved EBITDA loss, while monitoring cash runway and regional order timing risk.
What to watch
Cash is only $2.4M as of March 31, 2026; continued net losses ($3.2M FY) mean dilution/financing risk can dominate even with EBITDA improvement.
Background
Sonoma Pharmaceuticals develops stabilized hypochlorous acid (Microcyn) products (e.g., Reliefacyn) sold directly and via partners across multiple regions.
Ticker impact
Sonoma reported FY2026 revenue of $19.5M (+$5.2M YoY) and improved EBITDA loss 38% for the year, alongside Q4 revenue +48% YoY.
Bias toward modest upside/less downside volatility versus prior expectations, assuming no hidden balance-sheet deterioration beyond the disclosed $2.4M cash.
Revenue growth is broad-based (US/Europe/Rest of World) and EBITDA loss narrowed materially in both Q4 and FY, but the company still reports net losses and has limited cash, keeping risk elevated.
Market effects
Signals demand traction for hypochlorous-acid HOCl products and the company’s distribution expansion, relevant to small-cap healthcare/derm wound-care peers’ read-across.
US and Europe/Rest-of-World growth contrasted with Asia and Latin America order-timing declines, highlighting regional execution sensitivity.
Limited scale ($19.5M FY revenue) suggests mostly company-specific impact rather than broad market repricing.
Counterpoint
Revenue growth may be partly timing-driven (Latin America declines attributed to customer order timing), so sustainability of the run-rate could be weaker than it appears.
Key entities
- companySonoma Pharmaceuticals, Inc.
Nasdaq-listed developer/producer of stabilized hypochlorous acid (HOCl) products; reported FY2026 and Q4 results.
- productReliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel
Received National Psoriasis Foundation Seal of Recognition (Aug 2025) and National Rosacea Society Seal of Acceptance (Nov 2025), cited as business highlights.
